



23 October 2012

FerriScan contracted for two new Clinical Trials

Resonance Health has executed two multi-year contracts with a pharmaceutical company to provide FerriScan services, for an undisclosed sum.

One contract will involve Resonance Health working with up to 15 MRI facilities that will image patients participating in the clinical trial. Resonance Health will provide FerriScan image analysis services to measure liver iron concentration and a cardiac iron assessment for these patients. Resonance Health recently gained regulatory approval for the measurement of a parameter called cardiac T2* which provides an indirect assessment of cardiac iron overload.

In the second contract Resonance Health has been engaged to work with up to 20 MRI facilities across a number of countries and will provide a range of services to support the use of FerriScan in this clinical trial.

Resonance Health is pleased with the growing uptake of the Company's cardiac iron image analysis services and the medical community's recognition of FerriScan's superior performance for assessing liver iron concentration.

By Order of the Board Resonance Health Limited

For further information please contact:

Resonance Health Liza Dunne

Managing Director T: +61 8 9286 5300

E: <u>lizad@resonancehealth.com</u>

Naomi Haydari Company Secretary T: +61 8 9286 5300

E:naomih@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.